HN
Last reporting period 30 Jun, 2024
Updated 19 Sep, 2024
Last price
—
Market cap $B
0.284
Exchange
XSTO - Nasdaq STOCKHOLM AB
-4479 %
Last period ROIC
-3753%
ROIC has decreased in 5 years
What is ROIC ?
The return on invested capital ratio shows how much Net Operating Profit after Tax a company earns per unit of funds involved in its core business. The value of 20% is the benchmark for Eyestock Rating calculation.
See also Hansa Biopharma
Company Analysis
HNSA.ST valuation, rating, competitors, insights and company profile
Eyestock Rating
HNSA.ST financial analysis by Eyestock methodology
Valuation
HNSA.ST valuation using historical relative method
Statements
HNSA.ST Income Statements, Balance Sheet and Cash Flow Statements
Dividends
HNSA.ST dividend yield and annual dividend
The return on invested capital ratio shows how much Net Operating Profit after Tax a company earns per unit of funds involved in its core business. The value of 20% is the benchmark for Eyestock Rating calculation.
Hansa Biopharma`s ROIC for the last twelve months ended 2024-06-30 is -4479 %
